
|Articles|July 1, 2008
Oncology NEWS International
- Oncology NEWS International Vol 17 No 7
- Volume 17
- Issue 7
RAS Mutations Enhance Chemotherapy in AML
Among 185 patients with acute myeloid leukemia, 34 had RAS mutations and 22 received high-dose cytarabine after complete remission.
Advertisement
Among 185 patients with acute myeloid leukemia, 34 had RAS mutations and 22 received high-dose cytarabine after complete remission. Their relapse rate was 45%, compared with 68% for high-dose patients with normal RAS, according to a CALGB study published online (JCO June 16, 2008). This could allow doctors to identify patients who would benefit from aggressive therapy.
Articles in this issue
about 18 years ago
National Cancer Survivors Dayabout 18 years ago
New Indication for Velcade in Previously Untreated Myelomaabout 18 years ago
Risk Factors for Mantle Cell Lymphoma Identifiedabout 18 years ago
Antidiabetic Agent Metformin May Boost pCRs in Breast Caabout 18 years ago
Eisai Seeks Full FDA Approval for Ontak for CTCLabout 18 years ago
Symptom Screen Plus CA125 Detects Early Ovarian Caabout 18 years ago
Cisplatin Linked to Cardiac Complications in Testicular Ca Patientsabout 18 years ago
Updated X-ACT Study Results Presentedabout 18 years ago
ThromboGenics and BioInvent Announce Alliance with Rocheabout 18 years ago
Gene Signature Identifies Low-Risk Patients in MAGE-A3 TrialAdvertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma
3
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
4
What Does an End-of-Life Doula Do for Patients With Cancer?
5























































